Australia markets closed

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
132.04-0.49 (-0.37%)
As of 12:04PM EDT. Market open.
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
249,700
249,700
154,500
89,600
407,300
Depreciation & amortisation
21,300
21,300
15,600
10,900
8,600
Deferred income taxes
-56,700
-56,700
19,100
4,300
-310,700
Stock-based compensation
194,300
194,300
173,100
134,200
100,000
Change in working capital
28,200
28,200
-67,400
16,700
-37,900
Accounts receivable
-89,300
-89,300
-162,200
-28,400
-30,500
Inventory
5,400
5,400
-2,600
-2,500
-10,700
Other working capital
361,600
361,600
322,900
233,100
217,600
Other non-cash items
-200
-200
1,600
14,300
25,100
Net cash provided by operating activities
389,900
389,900
339,400
256,500
228,500
Cash flows from investing activities
Investments in property, plant and equipment
-28,300
-28,300
-16,500
-23,400
-10,900
Acquisitions, net
0
0
-42,700
0
-
Purchases of investments
-1,411,200
-1,411,200
-628,900
-804,700
-735,500
Sales/maturities of investments
972,400
972,400
511,000
697,900
750,500
Net cash used for investing activities
-467,100
-467,100
-177,100
-130,200
4,100
Cash flows from financing activities
Debt repayment
0
0
-279,000
-100
-186,900
Net cash used provided by (used for) financing activities
65,300
65,300
-234,300
27,400
-157,800
Net change in cash
-11,600
-11,600
-73,300
153,700
74,800
Cash at beginning of period
270,700
270,700
344,000
190,300
115,500
Cash at end of period
259,100
259,100
270,700
344,000
190,300
Free cash flow
Operating cash flow
389,900
389,900
339,400
256,500
228,500
Capital expenditure
-28,300
-28,300
-16,500
-23,400
-10,900
Free cash flow
361,600
361,600
322,900
233,100
217,600